

CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 13.11.2020

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Friday, 13.11.2020 at 5:00 p.m. at the registered office of the company the following were considered and approved:

1. Un-Audited financial results for the quarter and half year ended 30.09.2020. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.09.2020. **(Enclosed)**

The meeting concluded at 7:30 p.m.

This is for the information and records of the Exchange, please.


Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Koni Reddy
S. Koni Reddy
Whole-time Director & CEO
DIN: 02829319



Encl: as above



CONCORD DRUGS LIMITED

CIN No.: L24230TG1995PLC020093

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September 2020

[Rs. in Lakhs]


Particulars	Quarterly ended			half Year ended		Year ended
	30-Sep-20 (UnAudited)	30-Jun-20 (Un Audited)	30-Sep-19 (UnAudited)	30-Sep-20 (UnAudited)	30-Sep-19 (UnAudited)	31-Mar-20 (Audited)
I Revenue from Operations						
a. Net sales from Operations	1,656.674	1,820.32	1,409.43	3,476.998	2,740.51	5,133.89
b. Other Operating Income	4.488	2.15	2.15	6.640	5.31	12.01
II Other Income						
III Total Revenue (I+II)	1,661.162	1,822.48	1,411.59	3,483.638	2,745.81	5,145.89
IV Expenses						
a. Cost of Material Consumed	1,384.379	1,497.57	1,118.05	2,881.951	2,212.95	4,206.02
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	26.732	96.72	52.36	123.448	73.66	51.72
c. Employees Benefit Expenses	101.090	87.00	94.99	188.090	176.34	350.72
d. Finance Costs	48.896	43.91	44.62	92.805	87.32	154.37
e. Depreciation and Amortisation expense	33.041	31.73	36.84	64.772	73.22	146.39
f. Other expenses	56.124	43.20	56.33	99.320	95.63	191.03
Total Expenses	1,650.261	1,800.12	1,403.19	3,450.386	2,719.12	5,100.25
Profit/ (Loss) before Exceptional item and tax (III-IV)	10.901	22.35	8.40	33.252	26.69	45.65
V Exceptional Items						
VI Profit/ (Loss) before tax (V-VI)						
VII Tax Expense:						
a. Current tax	10.901	22.35	8.40	33.252	26.69	45.65
b. Deferred tax charge/credit	2.834	5.81	2.75	8.645	7.61	12.82
IX Profit/ (Loss) for the period (VII-VIII)	1.686	5.46	2.55	7.142	7.23	11.91
X Other Comprehensive Income	1.148	0.36	0.20	1.503	0.38	0.91
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	8.067	16.54	5.65	24.607	19.08	32.83
XI Paid-up equity share capital						
(Face value of the share- Rs. 10 each)	8.067	16.54	5.65	24.607	19.08	32.83
Other Equity						
XII Earnings per share (of Rs. 10 each)						
a. Basic (in Rs)						1,474.082
b. Diluted (in Rs)	0.092	0.19	0.06	0.281	0.22	0.38
	0.092	0.19	0.06	0.281	0.22	0.38

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th November, 2020
- The company operates in only one segment viz Pharmaceutical Products
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: November 13, 2020

By Order of the Board
For Concord Drugs Limited
S. Kamal Reddy
Managing Director
DIN: 01764665




Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana
Unaudited Balance sheet as at 30th September , 2020

Particulars	Note	As At Sep 30, 2020	As At March 31, 2020
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	991.604	973.86
(b) Capital Work-in Progress	3	124.731	99.77
(b) Investment property	3	78.598	78.60
Financial assets			
(a) Loans & Advances	5	69.306	53.62
Other Non current assets	4	35.726	39.29
Total Non - Current Assets		1,299.965	1,245.14
Current Assets			
Inventories	7	1,346.617	1,643.13
Financial assets			
(a) Investments			
(b) Trade receivables	6	2,695.594	2,544.60
(c) Cash and cash equivalents	8	412.980	1.21
(d) Bank balances other than (c) above	8	2.592	2.59
(e) Other Current Financial Assets	9	4.130	4.13
Other current assets	10	541.172	360.75
Total Current assets		5,003.086	4,556.40
Total Assets		6,303.052	5,801.55
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	874.375	874.38
Other equity	12	1,498.689	1,474.08
Total Equity		2,373.064	2,348.46
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	516.554	87.72
(b) Trade payables			
Deferred tax liabilities, net	14	15.208	13.70
Provisions	15	220.292	208.38
Government Grants	13	41.222	45.53
Total Non-current liabilities		793.276	355.34
Current liabilities			
Financial liabilities			
(a) Borrowings	16	873.140	869.10
(b) Trade payables	17	1,392.631	1,279.62
(c) Other Current financial liabilities	18	-	-
Current tax liabilities, net	15	7.142	11.91
Other current liabilities	19	863.799	937.13
Total Current liabilities		3,136.713	3,097.75
Total liabilities		3,929.988	3,453.09
Total Equity and liabilities		6,303.052	5,801.55

For and on behalf of the Board of Directors of
Concord Drugs Limited

CIN: L24230TG1995PLC020093



(Nagi Reddy Seelam)




(Koni Reddy Seelam)

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana			
Statement of Cash flow for the half year ended 30th September 2020			
Particulars	Rs in Lakhs		
	As at September 30 2020	As at March 31, 2020	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit Before Tax	33.25	45.65	
<u>Adjustments for:</u>			
Depreciation and amortisation expense	64.77	146.39	
Finance costs	81.45	144.60	
Interest income		(0.80)	
Provision for Gratuity		-	
Operating profit before working capital changes	179.48	335.84	
<u>Changes in working capital:</u> (Refer Note 40)			
<u>Adjustments for (increase) / decrease in operating assets:</u>			
Financial Assets			
Trade receivables	(151.00)	2,298.87	
Loans and Advances	(15.69)	(3.60)	
Other Non Current assets	3.57	(0.03)	
Inventories	296.51	221.03	
Other Current assets	(180.42)	(117.22)	
Other bank balances			
Other Current financial Assets			
<u>Adjustments for increase / (decrease) in operating liabilities:</u>			
Trade payables	113.01	(2,984.11)	
Borrowings			
Other current financial liabilities			
Other current liabilities	(73.33)	0.19	
Current tax liabilities, net	-4.77	518.16	
Provisions	11.91	(8.85)	
Deferred tax on amalgamation			
Cash generated from operations	179.27	260.28	
Net income tax paid	(7.14)	(11.91)	
Net cash flow from operating activities (A)	172.13	248.37	
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	(107.47)	(84.82)	
Proceeds from maturity of fixed deposits			
Others		0.80	
Net cash (used in) / flow from investing activities (B)	(107.47)	(84.02)	
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of equity shares		88.21	
Finance costs	(81.45)	(144.60)	
Repayment of Borrowings	428.83	18.75	
Repayment of short term Borrowings	4.04	(44.57)	
Govt Grants	(4.30)	(8.61)	
Other equity Adjustment		(88.20)	
Net cash flow (used in) financing activities (C)	347.11	(179.03)	
Net (decrease) in Cash and cash equivalents (A+B+C)	411.77	(14.67)	
Cash and cash equivalents at the beginning of the year	1.21	15.89	
Effect of exchange differences on translation of foreign currency Cash and cash equivalents			
Cash and cash equivalents at the end of the year (Refer Note (i) below)	412.98	1.21	
* Comprises:			
Balances with Banks	400.08	0.08	
Others	12.90	1.13	
	412.98	1.21	


For and on behalf of the Board of Directors of

Concord Drugs Limited

CIN: L24230TG1995PLC020093



(Naga Reddy Seelam)
Managing Director
DIN: 01764665



S. Koni Reddy
(Koni Reddy Seelam)
Director
DIN: 02829319



Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2020, and the year to date results for the period 1 April 2020 to 30 September 2020, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six month period ended 30 September 2019 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G Rao and Associates

Chartered Accountants

FRN:009399S



(CA G Nageswara Rao)

Partner

MNo:207300

UDIN No: 20207300AAAARS3633



Place: Hyderabad

Date: 13-11-2020